We compared the differential effects of positional isomers of acetyl salicylic acid (o-ASA, m-ASA, and p-ASA) on COX inhibition, gastric PGE 2 , MDA, plasma TNFα levels, SOD activity, HT-29 cell growth inhibition, cell proliferation, apoptosis, and cell cycle progression. We also evaluated the gastric toxicity exerted by ASA isomers. All ASA isomers inhibit COX enzymes, but only the o-ASA exerted an irreversible inhibitory profile. We did not observe a significant difference between ASA isomers in their ability to decrease the in vivo synthesis of PGE 2 and SOD activity. Furthermore, all isomers increased the levels of gastric MDA and TNFα when administered orally at equimolar doses. We observed a dose-dependent cell growth inhibitory effect, the order of potency was p-ASA > m-ASA ≈ o-ASA. There was a dose-dependent decrease in cell proliferation and an increase in apoptosis, with a concomitant G o /G 1 arrest. The ulcerogenic profile of the three ASA isomers showed a significant difference between o-ASA (aspirin) and its two positional isomers when administered orally at equimolar doses (1 mmol/kg); the ulcer index (UI) for o-ASA indicated extensive mucosal injury (UI = 38), whereas m-ASA and p-ASA produced a significantly decreased toxic response (UI = 12 and 8 respectively) under the same experimental conditions. These results suggest that the three positional isomers of ASA exert practically the same biological profile in vitro and in vivo, but showed different safety profiles. The mechanism of gastric ulcer formation exerted by aspirin and its two isomers warrants a more detailed and thorough investigation.
Introduction
2-acetoxybenzoic acid (acetylsalicylic acid or aspirin) is one of the most widely used over-thecounter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) to treat pain, fever, and inflammation. The major anti-inflammatory and analgesic mechanism of action of aspirin is the inhibition of cyclooxygenase (COX) enzymes (Vane, 1971) . COX-1 and COX-2 enzymes catalyze the first step in the enzymatic transformation of arachidonic acid (AA) to prostaglandins (PGs), prostacyclin, and thromboxanes (Txs) (Vane et al., 1998; Smith et al., 2000) . COX-1 is generally regarded as a constitutive enzyme that is present in most tissues; it is involved in the physiological production of PGs and provides maintenance functions such as cytoprotection in the stomach. In contrast, COX-2 has been regarded as an inducible enzyme (induced by cytokines, growth factor, interleukin-1-β, carrageenan) and is expressed in inflammatory cells (Masferrer et al., 1994) .
Among all NSAIDs, aspirin is a unique non-selective irreversible COX inhibitor because of its ability to acetylate the Ser530 hydroxyl group in the primary active site of COX-1 and COX-2 (Awtry and Loscalzo, 2000) . Acetylation of the weakly nucleophilic -OH of Ser530 by aspirin is thought to result from the initial binding of its COOH to Arg120 near the mouth of the COX binding site, which positions the o-acetoxy moiety in close proximity to the Ser530 -OH, which it acetylates. Orally administered aspirin irreversibly acetylates Ser530 of COX-1 and COX-2, leading to complete inhibition of COX-1 activity; nevertheless, the acetylated COX-2 active site remains active converting AA to 15-(R)-hydroxyeicosatetraenoic acid (15-R-HETE), which is the precursor to "aspirin-triggered" endogenous anti-inflammatory lipoxins (Serhan and Chiang, 2002; Yasuda et al., 2008) . Consequently, acetylation of COX enzymes by aspirin produces a desirable pharmacological profile, decreasing COX-1-derived PGs and Txs and stimulating the biosynthesis of COX-2-derived endogenous anti-inflammatory lipoxins. These are two of the essential effects that make aspirin an attractive drug in our program tool chest. Early observations showed that COX-2 is overexpressed in most premalignant and malignant neoplasms, and all essential features of carcinogenesis (mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, metastasis, and immunosuppression) are linked to COXderived PG biosynthesis (Qiao et al., 1995; Sheng et al., 1998; Kashfi and Rigas, 2005a; Harris, 2007) . Thus, it was reasonable to consider that COX-2 was a suitable molecular target for cancer treatment and/or cancer prevention, and NSAIDs may be useful in the treatment of COXexpressing tumors. Based on these hypotheses, NSAIDs (including selective COX-2 inhibitors) have been extensively studied as chemotherapeutic/chemopreventive agents. Evidence suggests that NSAIDs decrease the incidence of, or mortality from, breast cancer, (Holmes et al., 2010; Bardia et al., 2011) colon cancer, (Chan et al., 2007; Cole et al., 2009; Gao et al., 2009; Grau et al., 2009; Cooper et al., 2010) oesophageal cancer, Pandeya et al., 2010) non-small cell lung cancer, (Van Dyke et al., 2008) and others. However, there is conflicting evidence showing that the COX inhibitory potency of NSAIDs does not always correlate with their anticancer activity, suggesting that NSAIDs may exert their chemotherapeutic and chemopreventive properties by multiple mechanisms of action other than, or in addition to, COX inhibition (Kashfi and Rigas, 2005a; Kashfi and Rigas, 2005b; Grosch et al., 2006) .
Despite the wide variety of desirable pharmacological effects exerted by aspirin, there remains a significant risk of gastrointestinal bleeding, produced (presumably) by the inhibition of cytoprotective COX-mediated gastric PG synthesis, even with low prophylactic doses of this drug. (Yeomans et al., 2009) This mechanism-based toxicity is the main reason why the use of aspirin (and NSAIDs in general) has been correlated with a relatively high incidence of adverse gastrointestinal side effects, (Singh and Triadafilopoulos, 1999; Tenenbaum, 1999; Aalykke and Lauritsen, 2001; Fiorucci and Del Soldato, 2003; Schaffer et al., 2006) and has led some clinicians (and patients) to reduce their use (Scheiman and Fendrick, 2007) . In the last fifteen years, several research groups have reported extensive structure-activity relationships (SAR) on a wide variety of COX pharmacophores. In this regard, the attention was essentially focused on developing potent and selective COX-2 inhibitors based on the assumption that COX-2-derived PGs were uniquely and directly responsible for the inflammatory processes, and COX-1-derived PGs were mainly involved in cytoprotection; however, recent reports have challenged these "traditional" roles for COX-1 and COX-2 enzymes, emphasizing the importance of re-evaluating their roles in the inflammatory process, (Rouzer and Marnett, 2009 ) as well as their contribution in the underlying mechanisms of NSAID-induced side-effects.
Considering the simplicity of aspirin's chemical structure, it is surprising that there are no reports in the literature describing the SARs for the other two positional isomers of aspirin, namely the meta-and para-acetylsalicylic acid isomers. Therefore, as part of an ongoing research work aimed to develop new anticancer agents derived from aspirin, we now report a comprehensive biological evaluation of acetylsalicylic acid positional isomers, comparing their anti-inflammatory profile, their differential effects on cancer cell (HT-29) growth inhibition, cell proliferation, cell cycle, and apoptosis. We also evaluated the gastric ulcerogenic profile of aspirin's positional isomers, as well as a comprehensive molecular modeling (docking) study for the three isomers HPLC grade solvents and reagents acquired from Fisher chemicals were used; the colon adenocarcinoma HT-29 cell line (ATCC HTB-38, Manassas, VA), McCoy's 5A medium, and ovine COX-1 and COX-2 were obtained from Cayman chemicals (Ann Arbor, MI).
Animals. All experimental procedures were approved by the institutional animal research committee at the City College of New York, and performed in accordance with nationally approved guidelines for the treatment of laboratory animals. Male wistar rats (five per group, obtained from Charles River Laboratories Inc., Wilmington, MA) weighing 180-200 g were used.
The rats were fed with standard laboratory chow and water; however, before each experiment, the rats were fasted for 48 h but allowed to have free access to drinking water at all times. The experimental drugs were administered orally (gavage) by forming suspensions of o-ASA, m-ASA, or p-ASA (1 mmol/kg) in 1.0 mL of 1% carboxymethyl cellulose solution. The same volume of carboxymethyl cellulose solution was administered to the animals in the control group. Six hours after administration, the rats were euthanized by suffocation in a CO 2 chamber, and had their stomachs removed, cut along the greatest curvature, and rinsed with ice-cold distilled water. The ulcer index (UI) was determined for each experimental drug based on a previously reported procedure by Best et al. (Best et al., 1984) . Additionally, tissues from the rat stomachs were excised and processed to measure the levels of PGE 2 and malondialdehyde (MDA), as well as the activity of superoxide dismutase (SOD) enzyme. To determine plasma levels of TNF-α, blood samples from each rat were taken by cardiac puncture using heparin-containing vials.
This article has not been copyedited and formatted. The final version may differ from this version. (1 mM), and indomethacin (10 µM). Each tissue sample was homogenized and centrifuged for 10 min at 12,000 rpm (4°C), and then the amount of PGE 2 in supernatants (duplicate) was determined by an enzyme immunoassay kit (Cayman Chemical Inc., Ann Arbor MI) following the protocol described by the manufacturer. Briefly, the standard (50 μL) or homogenate (50 μL), enzymatic tracer (50 μL), and specific antiserum (50 μL) was mixed; after incubation for 17 h (overnight) at 4°C, the plates were washed with wash buffer, and Ellman's reagent (200 μL) was added into each well. The absorbance at 412 nm was measured after incubating the plate for 1 h at room temperature. The amount of detected prostaglandin was expressed as picograms of PGE 2 per milligram of protein; the protein levels were determined in a separate assay (Bio-Rad Laboratories, Hercules, CA). Superoxide dismutase activity. The activity of antioxidant enzymes (SOD) was determined in samples of gastric mucosal tissue isolated from each rat by a colorimetric assay kit (Cayman Chemical Inc., Ann Arbor MI) according to the protocol described by the manufacturer. Briefly, around 1 g of mucosal tissue was homogenized with 5 mL of 20 mM HEPES buffer (pH 7.2) containing EGTA (1 mM) and sucrose (300 mM). Then, cell homogenates were centrifuged at 1500 rpm for 10 min (4°C). The supernatants were removed and stored at −80°C until assayed.
SOD activity was determined using a spectrophotometric method measuring absorbance at 460 nm; the results were expressed as units of SOD activity per milligram of protein. In this regard, one unit of SOD is defined as the amount of enzyme required to exhibit 50% dismutation of the superoxide radical.
Plasma TNF-α levels. Fresh samples of blood from animals were collected by cardiac puncture, receiving the fluid into heparin-containing vials. TNF-α plasma levels were determined using an enzyme immunoassay kit (R&D Systems, Minneapolis, MN) according to the protocol described by the manufacturer; the results were expressed as picograms of TNF-α/mL. Briefly, each sample (50 μL) was incubated with antibodies specific for rat TNF-α, and then the samples were washed three times with assay buffer. An enzyme-linked polyclonal antibody specific for rat TNF-α (conjugated to horseradish peroxidise) was added to the wells. After washing unbound antibody-enzyme complexes, a substrate solution containing tetramethylbenzidine (TMB) and hydrogen peroxide were added to the wells. This enzymatic reaction yielded a blue product (oxidized TMB) that turned yellow when we added dilute hydrochloride acid. The intensity of the color by spectrophotometry was determined measuring optical densities (OD) at 450 nm in a standard enzyme-linked immunosorbent assay plate reader. The sensitivity of this assay was determined (around 1.6 pg/mL) by adding 2 standard deviations to the mean OD value of 20X
This article has not been copyedited and formatted. The final version may differ from this version. The percentage of apoptotic cells was calculated using a Becton Dickinson LSR II, equipped with a single argon ion laser. For each subset, about 10,000 events were analyzed. All the parameters were collected in list mode files, and the data was analyzed using the Flow Jo software.
The levels of proliferating cell nuclear antigen (PCNA) was determined using an ELISA Kit (Calbiochem, La Jolla, CA), in accordance with the manufacturers protocol. Briefly, HT-29 cells were incubated with serum-free media for 24 hours to remove the effect of endogenous growth factors. Then, the cells (1×10leupeptin, and 50 mM Tris-HCl, pH 8.0). The samples of the suspension were pipetted into the wells of the plate containing rabbit polyclonal antibody (specific for the human PCNA protein)
included with the kit. Then, mouse monoclonal antibody clone PC10 (detector antibody) was added to each well, and the mixture was incubated for 2h at room temperature. After washing the wells, horseradish peroxidase streptavidin solution was added, and the plate was incubated for 30 min at room temperature; the chromogenic substrate tetramethylbenzidine was added and the plates were incubated again for a further 30 min. Finally, the stop solution was added and the absorbance was measured in each well at 450 nm.
Cell cycle analysis. Cell cycle phase distributions of control were obtained and HT-29 cells were treated by using a Coulter Profile XL equipped with a single argon ion laser. For each subset, >10,000 events were analyzed. All the parameters were collected in list mode files. The data was analyzed on a Coulter XL Elite Work station using the software programs Multigraph TM and of reaction buffer for 30 min at 4°C. After incubation, the samples were loaded into microdialysis chambers (10-kDa molecular mass cut-off membrane, Amicon Inc.) and dialyzed against 500 μL of inhibitor-free reaction buffer for 2 hr. After dialysis, the remaining enzymatic activity was determined as described above (without adding more inhibitor).
Ulcerogenicity. Two different experiments were conducted to compare the gastric toxicity exerted by the three aspirin isomers, namely the ulcer index (UI) and the erosion index (EI) assays. The ulcer index (UI) was determined as described by Best et al (Best et al., 1984) . o-ASA, m-ASA, or p-ASA (1 mmol/kg) were administered by gavage, suspended in 1% carboxymethyl cellulose solution (1.0 mL). Animals in the control group received an equivalent volume of vehicle. UI measured clearly visible ulcers (elongated, hemorrhagic lesions varying in length); whereas EI measured less noticeable micro-hemorrhagic lesions, which were only observed using a magnifying lens. were constructed using the Build Fragment tool and minimizing the energy for 1000 iterations until reaching a convergence equal to, or lower than 0.01 kcal/mol Å. The docking experiment on COX-1 (PDB file 1prh) was carried out by suitably positioning the energy minimized ligand in the active site while carefully monitoring non-bonded interactions of the ligand-enzyme assembly and any side chain bumps; in contrast, the docking experiment on COX-2 was carried out by superimposing the energy minimized ligand on SC-558 in the PDB file 1cx2, at which point we deleted the structure of SC-558. In all experiments, the resulting ligand-enzyme complex was docked using the Libdock command (protocol of Discovery Studio) after defining subsets of the enzyme within a 10 Å radial distance from the ligand. In this regard, the force field Chemistry HARvard Macromolecular Mechanics (CHARMM) was employed for all docking experiments. Subsequently, a molecular dynamics (MD) simulation was conducted with the corresponding ligand−enzyme complex using a simulation protocol at a temperature of 300 K, a 100 step equilibration/1000 iterations, a time step equal to 1 fs, and a distance-dependent dielectric constant 4r. Finally, (by 1000 iterations) the optimal binding orientation of each ligand−enzyme complex was minimized by using the conjugate gradient method until reaching a convergence = 0.001 kcal/mol Å. The different intermolecular energies (Eintermolecular) between the ligand and the enzyme were evaluated and compared and, expressed in kcal/mol.
Statistics. All data are presented as the mean ± SEM, with sample sizes of at least 5 rats/group (unless otherwise specified). Comparisons between groups were performed using a one-way analysis of variance followed by the Student-t test.
This article has not been copyedited and formatted. The final version may differ from this version. This represents about 86% reduction in PGE 2 levels in gastric tissue compared to the control group; however, we did not find a statistically significant difference between the three ASA isomers, since m-ASA (9.7 ± 1.0 pg/mg protein) and p-ASA (10.7 ± 1.5 pg/mg protein) decreased the biosynthesis of PGE 2 to the same extent as compared to o-ASA (11.8 ± 1.2 pg/mg protein). These results are shown in Figure 2A . produced a significant increase in the expression of the pro-inflammatory mediator TNFα, compared to that obtained in samples of gastric mucosa from control rats. In this regard, we determined the basal levels of TNFα in animals receiving vehicle (control group) to be 5.2 ± 1.3 pg/mL, whereas the levels of this protein in treatment groups increased to 194.9 ± 3.1 pg/mL (o-ASA), 181.5 ± 4.3 pg/mL (m-ASA), and 187.7 ± 2.9 pg/mL (p-ASA). Based on these results, all three positional isomers of ASA were equally potent in increasing plasma TNFα levels, Figure   2D . The distance between the acetoxy group and the carboxylic acid moiety present in acetylsalicylic acid isomers was not a determinant for inducing apoptosis (see Figure 4A ).
Index of Lipid
Cancer
Cell Proliferation.
To elucidate the mechanism underlying the effect of ASA isomers on cancer cell growth, we also determined the modulatory effect exerted by o-ASA, m-ASA, and p-ASA on cell proliferation. In this regard, we measured the expression of proliferating cell nuclear antigen (PCNA) in human adenocarcinoma HT-29 cells incubated for 24 h in the presence of ASA isomers (1, 3, and 5 mM). We observed that all ASA isomers exerted a dose-dependent decrease in cancer cell proliferation by reducing PCNA expression in HT-29 cells from 100 % in the control group, to 57-87% in treated cells (see Figure 4B) . At 1 mM, the three ASA isomers exerted a non-significant reduction in PCNA expression; however, this decrease was significant 
Cyclooxygenase Inhibition assay. We determined the percent of enzyme inhibition exerted
by o-ASA, m-ASA, and p-ASA isomers following two different protocols. In the first protocol, we carried out a concentration-dependent (1, 3, 5 mM) COX inhibition (Table 1) , whereas in the second protocol, we measured the percent of COX-1 inhibition exerted by m-ASA at different time points (2, 5, 15, 30, and 120 min) at 1mM (Table 2) . To estimate the extent of irreversible acetylation exerted by the different ASA isomers, we determined the percent of COX inhibition after filtration of the corresponding inhibitor solution by microdialysis.
Results obtained in the first protocol showed a concentration-dependent COX inhibition exerted by o-ASA, m-ASA, and p-ASA. In this regard, we observed that aspirin (o-ASA) exerted a marked inhibitory profile on COX-1 by inhibiting the catalytic activity of this enzyme (72-93% inhibition) within the range of concentrations used (1-5 mM), and this profile did not change after replacing the medium by microdialysis (Table 1) . However, the inhibitory profile exerted by the other two ASA isomers was significantly lower at 1 mM (o-ASA = 54%, m-ASA = 48%) and 3 mM (o-ASA = 63%, m-ASA = 71%). In contrast, we observed that at 5 mM, the three ASA compounds exerted a significantly lower COX-1 inhibitory profile after microdialysis (see Table   1 ).
In regards to COX-2 inhibition, we observed that before microdialysis, the three ASA isomers exerted the same degree of enzyme inhibition. For example, the o-ASA isomer inhibited COX-2 by 83 ± 2 and 95 ± 2% at 3 and 5 mM respectively, whereas the m-ASA and p-ASA isomers inhibited this enzyme by 80 ± 2%, 80 ± 3% at 3 mM, and 99 ± 3, 94 ± 4 at 5 mM. However, as it was noted for COX-1 inhibition, only the o-ASA isomer exerted the same degree of COX-2 inhibition before and after microdialysis, since the other two isomers exerted a significantly lower inhibitory profile after microdialysis. For example, the m-ASA isomer inhibited COX-2 by 56 ± 3 at 3 mM after the microdialysis protocol, compared to 80 ± 2% before microdialysis at the same concentration. The same trend was observed for this compound at 5 mM (99 ± 3 and 76 ± 4% inhibition before and after dialysis respectively).
The second protocol showed that m-ASA decreased the enzymatic activity of COX-1 in a timedependent manner. However, this time-dependent inhibition was observed only within the first 30 min, because at the last time-point (120 min) we observed an 11% decrease in potency (43% inhibition compared to 54% at 30 min). As it was noted for the concentration-dependent experiments described above, in the time-dependent protocol we also observed a significant decrease in potency after removal of the inhibitor by microdialysis (Table 2) .
Ulcerogenicity. We carried out two different assays to evaluate the toxic side-effects exerted by an acute oral equimolar (1 mmol/kg) dose of o-ASA, m-ASA, and p-ASA isomers. In the first experiment, we determined macroscopic ulcerative lesions in the glandular region of the rat stomach ("ulcer index"; Figure 6A ), in the second one we determined smaller points (erosions) on the stomach epithelial layer ("erosion index"; Figure 6B ), which are only visible using a magnifying lense. In this regard, animals in the control group showed a normal glandular region with no ulcers or erosions on the luminal surface (UI = EI = 0). As expected, the administration Moreover, the acetoxy CH 3 group underwent nonpolar binding interactions (< 5 Å) with Val349 and Leu531. This indicates that the C-2 acetoxy group in aspirin is suitably positioned to irreversibly acetylate Ser530.
Docking aspirin in COX-2.
The most stable enzyme-ligand complex ( Figure 7D ) showed that the central phenyl ring of aspirin was oriented in a region at the centre of the active site surrounded by Val349, Leu352, Leu384, Trp387, Met522, Val523, and Ala527 (distance < 5 Å).
The C-1 carboxylate was oriented close to the mouth of the COX-2 active site, and the 7C ) showed that the central phenyl rings were oriented in a hydrophobic region at the centre of the active site surrounded by Leu352, Phe518, Ile523, Met522, and Ala527 (distance < 5 Å).
The C-1 carboxylate of both m-ASA and p-ASA was oriented toward the mouth of the active site closer to the polar amino acids Arg120 and Tyr355. As noted for aspirin, the carboxylate (COOH) moieties in m-ASA and p-ASA were about 3.6 and 3.5 Å away from OH of Tyr355 respectively, undergoing electrostatic interactions with both hydrogen atoms of NH 2 of Arg120 (distance < 2.5 Å). The C-3 acetoxy group (OCOCH 3 ) was oriented toward the apex of the COX-1 active site (Leu352, Typ385, and Trp387), which locates their C=O ester group near (about 4.3-5.5 Å away) from OH of Ser530. This suggests that, despite the meta and para relationships between the carboxy and the ester groups in these ASA isomers, the acetoxy moiety is still located near polar amino acids at the active site and favors the orientation of the acetoxy groups toward Ser530, the acetylation site for aspirin.
Docking ASA isomers in COX-2. We observed that the central phenyl rings were also oriented in a hydrophobic region at the centre of the COX-2 active site surrounded by Val349, Leu352, Ser353, and Val523 (around 5 Å away). The C-1 carboxylate of the two aspirin derivatives was oriented close to the mouth of the COX-2 active site; the carboxylate COOH moieties formed a hydrogen bond with OH of Tyr355 (distance = 3.2 and 3.4 Å for m-and p-ASA respectively), and were about 4.1-5.8 Å away from Arg120. Due to the presence of a small Val523 in the COX-2 active site, we observed that the phenyl ring with the C-1 acid substituent in m-ASA was able to interact with polar amino acid residues (His90 and Arg513) present in the secondary pocket of COX-2; this was not the case for p-ASA. These observations indicate that the COOH group in m-ASA acted as an anchor orienting the acetoxy group toward Ser530, the acetylation site of aspirin. However, for both isomers, the C-3 acetoxy substituent (OCOCH 3 ) was oriented toward the apex of the active site in a hydrophobic region comprised of Leu384, Tyr385, Trp387, Phe518, and Met522 (distance < 5 Å), and the distances between the acetoxy group (OCOCH 3 ) in m-ASA and p-ASA and the OH of Ser530 (the acetylation site of aspirin), were about 6.75 and 5.6 Å respectively (see Figures 7E and F) . 
Discussion
The major pharmacological mechanism of action exerted by NSAIDs is the inhibition of COX-1 and COX-2 enzymes. Aspirin is the only NSAID that irreversibly inhibits both enzymes, decreasing the amount of pro-inflammatory prostaglandins; consequently, aspirin also decreases the production of cytoprotective PGE 2 in vivo (Ligumsky et al., 1982; Lichtenberger et al., 2007) When administered at equimolar doses (1 mmol/kg p.o.), o-ASA, m-ASA, and p-ASA exerted the same biological profile, which suggests that all acetylsalicylic acid isomers inhibited, to the same extent, COX-derived PGE 2 synthesis in gastric tissue. In the present study, we did not evaluate the anti-inflammatory profile of ASA isomers, but according to these results, it is reasonable to assume that regardless of positional isomerism, the acetylsalicylic acid COX pharmacophore is equally effective in decreasing the biosynthesis of PGs locally and systemically.
The enzymatic inhibition of COX enzymes exerted by aspirin (IC 50 values) reported in the literature varies considerably, depending on the experimental conditions used for the particular assay. In the present study, we have worked with an in vitro system with purified ovine COX-1 and COX-2 resuspended in a reaction buffer with no cell fractions, thus excluding enzymatic degradation of ASA isomers by non-specific esterases. The irreversible inhibition of COX enzymes exerted by o-ASA is demonstrated by comparing the activity of COX-1 and COX-2 before and after microdialysis, which after 30 min of incubation eliminates any unbound drug from the enzyme suspension by filtration through a semi-permeable membrane. We observed that only the o-ASA isomer showed the same degree of inhibition before and after microdialysis, whereas the m-ASA and p-ASA isomers showed lower inhibitory profiles after the drug was removed. This may suggest that either the m-ASA and p-ASA exert a lower degree of acetylation in the active site compared to o-ASA, or they reversibly inhibit COX-1 and COX-2 enzymes. In this regard, we used indomethacin as reference drug. After dialysis, the potency of indomethacin decreased considerably from 69% to 24% on COX-1, and from 67% to 32% inhibition on COX-2, which clearly showed a reversible pattern of enzyme inhibition.
To investigate the potential irreversible inhibition of COX enzymes exerted by the three ASA isomers, we carried out a series of molecular modeling (docking) studies to evaluate their differential binding interactions within the active site of COX enzymes. As expected, the acetyl group in o-aspirin was oriented toward the Ser530 residue in both proteins; however, we observed that despite a few differences in orientation between m-and p-ASA isomers, these compounds also adopt relatively favorable conformations which may lead to acetylation of Ser530. This observation is supported by the bioequivalent in vivo profile (decrease in PGE 2 levels) exerted by all ASA isomers when administered orally to rats.
The significant increase in the levels of MDA in samples of gastric tissue, suggests that o-ASA, m-ASA, and p-ASA induced oxidative stress to the same extent. According to our results, changes in the relative position of the carboxylic acid group relative to the acetoxy group did not alter the well established tendency of aspirin (Chattopadhyay et al., 2010) to induce an intracellular oxidative environment. This observation correlates well with the observed decrease in the activity of SOD in gastric tissue. In a previous study, our group reported the inhibitory activity of aspirin on this antioxidant enzyme; (Chattopadhyay et al., 2010) according to the results obtained in the present work, the other two ASA isomers are equally suited to decrease the catalytic activity of SOD. Furthermore, we observed that all ASA isomers exerted an upregulation of the pro-inflammatory mediator TNFα, which has been reported to trigger the adherence and activation of leukocytes, leading to the release of oxygen-derived free radicals (oxygen superoxide) and proteases, producing epithelial injury (Perini et al., 2004) . However, despite these observations suggesting that all ASA isomers would exert the same degree of gastric toxicity, we were surprised to see that, according to the ulcer index assay, the o-ASA was significantly more ulcerogenic than the m-ASA or p-ASA isomers. This piece of information The use of NSAIDs has been correlated with a lower incidence of colon cancer among regular users of these drugs (Chan et al., 2007; Cole et al., 2009; Gao et al., 2009; Grau et al., 2009; Cooper et al., 2010) . We know that NSAIDs induce apoptosis in many cells and in response to different stimuli. Proposed mechanisms for the pro-apoptotic effects include activation of caspases, induction of cytochrome c release, regulation of protein kinase C, inhibition of NF-κB, and suppression of AP-1 (Wong et al., 2004 ). In the current study, we determined that there was a significant difference between ASA isomers in their ability to inhibit cancer ( In conclusion, the observed structure-activity relationships among ASA isomers, suggests that m-ASA and p-ASA should be considered equivalent to aspirin from a pharmacological point of view, because despite differences observed in the in vitro assays, all ASA isomers decreased PGE 2 levels to the same extent in vivo. Moreover, the marked similarities in the synthesis of MDA, expression of TNFα, and inhibition of antioxidant SOD in gastric tissue, there is a significant difference between different ASA isomers in their ability to produce gastric ulcers when administered orally, which warrants further studies to explore the potential use of relatively safer ASA analogues possessing either a meta-or para-relationship between the COOH and COCH 3 moieties.
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